Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1938 1
1939 5
1940 1
1941 1
1942 1
1946 2
1947 3
1948 5
1949 2
1950 12
1951 13
1952 35
1953 21
1954 9
1955 12
1956 9
1957 22
1958 17
1959 21
1960 11
1961 13
1962 28
1963 48
1964 34
1965 42
1966 43
1967 40
1968 32
1969 40
1970 41
1971 40
1972 55
1973 60
1974 64
1975 61
1976 94
1977 84
1978 89
1979 125
1980 140
1981 169
1982 222
1983 209
1984 259
1985 294
1986 311
1987 384
1988 394
1989 428
1990 523
1991 574
1992 633
1993 752
1994 825
1995 979
1996 1114
1997 1330
1998 1484
1999 1832
2000 2160
2001 2500
2002 2988
2003 3488
2004 4169
2005 5046
2006 5805
2007 6339
2008 7422
2009 8175
2010 9262
2011 10530
2012 12066
2013 13220
2014 14815
2015 15946
2016 16945
2017 18083
2018 19807
2019 22496
2020 26094
2021 5814
Text availability
Article attribute
Article type
Publication date

Search Results

222,381 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Zhuorui
Page 1
Did you mean zhaohui lu (175 results)?
Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis.
Seifert R, Kessel K, Schlack K, Weckesser M, Bögemann M, Rahbar K. Seifert R, et al. Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2106-2112. doi: 10.1007/s00259-020-04703-3. Epub 2020 Feb 16. Eur J Nucl Med Mol Imaging. 2020. PMID: 32062682 Free PMC article.
Various studies have evaluated the efficacy and safety of [(177)Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval. ...However, future studies are needed to elucidate the dose-related efficacy of [(177)Lu]Lu-PSMA-617 as a way to pers …
Various studies have evaluated the efficacy and safety of [(177)Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy i …
Modelling of the (177m)Lu/(177)Lu radionuclide generator.
Bhardwaj R, Wolterbeek HT, Denkova AG, Serra-Crespo P. Bhardwaj R, et al. Appl Radiat Isot. 2020 Dec;166:109261. doi: 10.1016/j.apradiso.2020.109261. Epub 2020 Jul 10. Appl Radiat Isot. 2020. PMID: 32961525 Free article.
In order to determine the potential of (177m)Lu/(177)Lu radionuclide generator in (177)Lu production it is important to establish the technical needs that can lead to a clinically acceptable (177)Lu product quality. ...The dissociation rate constants l …
In order to determine the potential of (177m)Lu/(177)Lu radionuclide generator in (177)Lu production it is important to …
(177)Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy.
Banerjee SR, Kumar V, Lisok A, Chen J, Minn I, Brummet M, Boinapally S, Cole M, Ngen E, Wharram B, Brayton C, Hobbs RF, Pomper MG. Banerjee SR, et al. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2545-2557. doi: 10.1007/s00259-019-04434-0. Epub 2019 Aug 10. Eur J Nucl Med Mol Imaging. 2019. PMID: 31399803
Efficacy and toxicity after 8 weeks were evaluated at a single administration of 111 MBq for (177)Lu-L1, (177)Lu-L3, (177)Lu-L5 and (177)Lu-PSMA-617. Efficacy of (177)Lu-L1 was further investigated using different doses, and long-term toxicity w …
Efficacy and toxicity after 8 weeks were evaluated at a single administration of 111 MBq for (177)Lu-L1, (177)Lu-L3, (177)L
Preliminary Studies of (177)Lu-Diethylenetriamine Penta-Acetic Acid-Deoxyglucose in Hepatic Tumor-Bearing Mice.
Zhou L, Chen L, Yang L, Cai L, Liu L, Zhao Y, Feng Y, Liu N, Zhao Y, Xia Y, Wei H, Chen Y. Zhou L, et al. Cancer Biother Radiopharm. 2020 Feb;35(1):33-40. doi: 10.1089/cbr.2019.2903. Epub 2019 Nov 21. Cancer Biother Radiopharm. 2020. PMID: 31750727
The cellular uptake of (177)Lu-DTPA-DG was much higher than that of the (177)Lu-DTPA. The biodistribution of (177)Lu-DTPA-DG demonstrated that the complex accumulated in the tumor with high tumor/blood and tumor/muscle ratios. The tumors in mice in the (177) …
The cellular uptake of (177)Lu-DTPA-DG was much higher than that of the (177)Lu-DTPA. The biodistribution of (177)Lu-DT …
Preparation of [(177)Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 for radiotherapy of insulinoma: a detailed insight into the radiochemical intricacies.
Guleria M, Das T, Amirdhanayagam J, Sarma HD, Dash A. Guleria M, et al. Nucl Med Biol. 2019 Nov-Dec;78-79:31-40. doi: 10.1016/j.nucmedbio.2019.11.003. Epub 2019 Nov 9. Nucl Med Biol. 2019. PMID: 31731177
INTRODUCTION: [(177)Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 ([(177)Lu]Lu-DOTA-Exendin-4) is a potential agent for radiotherapy of insulinomas owing to its specificity towards GLP-1 (Glucagon like peptide-1) receptors over-expressed on such cancers. ...Bio-distr …
INTRODUCTION: [(177)Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 ([(177)Lu]Lu-DOTA-Exendin-4) is a potential agent for radioth …
Biodistribution, Pharmacokinetics, and Dosimetry of (177)Lu-, (90)Y-, and (111)In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist (177)Lu-DOTATATE: The Mass Effect.
Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, Fani M. Nicolas GP, et al. J Nucl Med. 2017 Sep;58(9):1435-1441. doi: 10.2967/jnumed.117.191684. Epub 2017 Apr 27. J Nucl Med. 2017. PMID: 28450554 Free article.
In this preclinical study, the SSTR2 antagonist OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH(2)]) labeled with (177)Lu, (90)Y, and (111)In was compared with the SSTR2 agonist (177)Lu-DOTATATE. ...Clinical studies are warranted to confi …
In this preclinical study, the SSTR2 antagonist OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH(2)]) labeled wit …
Comparison of biological properties of [(177) Lu]Lu-ProBOMB1 and [(177) Lu]Lu-NeoBOMB1 for GRPR targeting.
Rousseau E, Lau J, Zhang Z, Zhang C, Kwon D, Uribe CF, Kuo HT, Zeisler J, Bratanovic I, Lin KS, Bénard F. Rousseau E, et al. J Labelled Comp Radiopharm. 2020 Feb;63(2):56-64. doi: 10.1002/jlcr.3815. Epub 2020 Jan 11. J Labelled Comp Radiopharm. 2020. PMID: 31715025
Lu-NeoBOMB1 had better binding affinity for GRPR than Lu-ProBOMB1 (K(i) values: 2.26 0.24 and 30.2 3.23nM). [(177) Lu]Lu-ProBOMB1 was obtained in 53.7 5.4% decay-corrected radiochemical yield with 444.2 193.2 GBq/mumol molar activity and >95% radioc
Lu-NeoBOMB1 had better binding affinity for GRPR than Lu-ProBOMB1 (K(i) values: 2.26 0.24 and 30.2 3.23nM). [(177) Lu]
Large-scale production of lutetium-177m for the (177m)Lu/(177)Lu radionuclide generator.
Bhardwaj R, Ponsard B, Sarilar M, Wolterbeek B, Denkova A, Serra-Crespo P. Bhardwaj R, et al. Appl Radiat Isot. 2020 Feb;156:108986. doi: 10.1016/j.apradiso.2019.108986. Epub 2019 Nov 16. Appl Radiat Isot. 2020. PMID: 31786419
In this work, (177m)Lu has been produced by irradiation of natural Lu(2)O(3) targets at the BR2 reactor (Mol, Belgium) and the obtained data together with literature values have been used to theoretically investigate the production of (177m)Lu at different ne …
In this work, (177m)Lu has been produced by irradiation of natural Lu(2)O(3) targets at the BR2 reactor (Mol, Belgium) and the …
Radionuclide generator-based production of therapeutic (177)Lu from its long-lived isomer (177m)Lu.
Bhardwaj R, Wolterbeek HT, Denkova AG, Serra-Crespo P. Bhardwaj R, et al. EJNMMI Radiopharm Chem. 2019 Jul 15;4(1):13. doi: 10.1186/s41181-019-0064-5. EJNMMI Radiopharm Chem. 2019. PMID: 31659496 Free PMC article.
BACKGROUND: In this work, a lutetium-177 ((177)Lu) production method based on the separation of nuclear isomers, (177m)Lu & (177)Lu, is reported. ...The liquid-liquid extractions were performed periodically for a period up to 35 days. RESULTS: A maximum ( …
BACKGROUND: In this work, a lutetium-177 ((177)Lu) production method based on the separation of nuclear isomers, (177m)Lu &amp …
Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [(177)Lu]Lu-DOTA-TATE in Lewis rats.
Zellmer J, Yen HY, Kaiser L, Mille E, Gildehaus FJ, Böning G, Steiger K, Hacker M, Bartenstein P, Todica A, Haug AR, Ilhan H. Zellmer J, et al. EJNMMI Res. 2020 Apr 25;10(1):41. doi: 10.1186/s13550-020-00628-y. EJNMMI Res. 2020. PMID: 32335736 Free PMC article.
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with [(177)Lu]Lu-DOTA(0),TYR(3)-octreotate ([(177)Lu]Lu-DOTA-TATE) and the mechanistic target of rapamycin (mTOR) inhibitor everolimus are both approved for the treatment of neuroendocrine tumours ( …
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with [(177)Lu]Lu-DOTA(0),TYR(3)-octreotate ([(177)Lu]Lu-DO …
222,381 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page